TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Number of Risky Sexual Partnerships
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in HIV Testing Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Two-year rate of failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Total Dandruff Severity Score (TDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Men With a Positive MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual blood loss volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Serum Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Terminal Phase Elimination Half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Average Wearing Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Minimal residual disease level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With VZV Antibody Levels >=5 gpELISA Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer of VZV Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scoring of individual exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve at Steady State Over the Dosing Interval (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of complete and partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: duration of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarker assays exceeding threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly Walking Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who have consumed new psychoactive substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Functional Dyspepsia Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of healing at 3 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of pulmonary infections
Endpoint domain: Adverse events/effects
Primary endpoint: GERD-Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: RESQ-7 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of POC CCA urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Physician Interventions Needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with acute grade 2 or greater acute GU toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Treatment-related TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in activity level/exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum/plasma markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restless Legs Syndrome Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restless Legs Syndrome-Quality of Life Instrument (RLS-QLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Johns Hopkins Restless Legs Severity Scale (JHRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Restless Legs Syndrome Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to change the tracheal cannula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Percentage of fallers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous and non-invasive skin temperature at the lateral rib cage position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous and non-invasive heat flux at the lateral rib cage position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous and non-invasive skin temperature at the foot position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous and non-invasive heat flux at the lateral foot position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sporadic rectal temperature measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sporadic ear temperature measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insomnia Severity Index total score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Patients number with high tryptase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Close
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central aortic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Cerebral Blood Flow (CBF) at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: mRS score in 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke recurrence within 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Neonatal rectal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-sectional area of abductor hallucis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cross-sectional area of flexor digitorum brevis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thickness of flexor hallucis brevis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IFM strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects Who Achieved Complete Clearing of Corneal Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc Prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accrual success
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vitamin D levels in preterm adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise heart rate in preterm adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function capacity in preterm adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saturation of blood oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VAS score for maternal pain on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of MR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioral Measure of Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Moderate to Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Wellness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ICH size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Change From Baseline in Hot Flash Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Hot Flash Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Response Conversion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptance and Action Questionnaire (AAQ-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Home Situation Questionnaire (HSQ-ASD)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Clinical Pregnancy Rate Per Embryo Transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Level of immunization (seroprevalence) to COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of Fluid in the Lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Initial Sleep Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean difference in change from baseline SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in quality of life after procedure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alcohol Cue-elicited Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of hand foot syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient reported pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean Change From Baseline in Disease Activity Score (DAS)28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Tender Joint Count (TJC) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Swollen Joint Count (SJC) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of cortical excitability using Transcranial Magnetic Stimulation (TMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of neural excitability using Magnetic resonance imaging (MRI) scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of neural excitability using electroencephalogram (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of the upper extremity motor function using Fugl-Meyer scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of upper extremity performance (coordination, dexterity and functioning) using Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to severe disease
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in PROMIS Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in ASCQ-Me
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in PROMIS Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Creatinine Clearance Calculated and Corrected According to Cockcroft Gault at Month 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in 24-Hour Urinary Protein at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Forced expiratory volume in the 1st second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recall incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Histamine provocative concentration causing 20% fall in FEV1 (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Average weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Bupivacaine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: platelet count decreased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: absolute neutrophil count decreased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Direct Cardio-respiratory fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sum norepinephrine (NE) equivalent dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IGFBP3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGF-1/IGFBP3 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in T2 Weighted Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical swallowing Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy (sensitivity, specificity, predictive positive value, negative predictive value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval delays in access to emergency care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adenoma detection rate in the right colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arrhythmia-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Depressive Symptom load
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotion Regulation Competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: size of coronary aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence rate of Oxygenation index ≤ 300 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Reporting Severe Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing the Study Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of keratometry (Km)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of the maximum keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of index of surface variance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of the Belin/Ambrósio Enhanced Ectasia Display (BAD-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without paraplegia or complications
Endpoint domain: Mortality/survival
Primary endpoint: Dark adaptation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Foveal retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of foveal avascular zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accommodation Lag 5D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Patients Reporting Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Patients Reporting Ophthalmic Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients without diagnosis of new dementia
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients without persistent disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving ACR20 Response at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in HAQ-DI Score at Month 3
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving DAS28-4 (ESR) Less Than 2.6 at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrauterine growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse or serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: percentage change in intra-ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Clinical Response at Week 10 in Induction Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' perspective on decision-making factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in dysphagia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of BEACOPP specific toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: five time repeated instrumented time up and Go Test (5iTUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Splanchnic venous capacitance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants in Remission Based on ASEX Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants in Remission Based on MGH-SFQ Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Aqueous Humor Bromfenac Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Discontinuation of Systemic Immunosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants treated with isotoxic RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of monthly migraine periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Percent Hepatic Fat Fraction (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sebum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dehydroepiandrosterone sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Leg Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ASCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physiological data collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes